Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于2025年度计提资产减值准备及预计负债的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Heyuan Biotechnology (Group) Co., Ltd. regarding the 2025 fiscal year asset impairment provisions and estimated liabilities. It details the amounts of impairment losses and provisions made for various asset categories as of December 31, 2025, including credit impairment losses, inventory write-downs, contract asset impairment, and long-term asset impairment. The document also includes the board audit committee's opinion confirming the appropriateness and compliance of these provisions with accounting standards. The document is relatively short (1993 characters) and is an announcement of accounting estimates and provisions rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification letter or a regulatory compliance filing. The content focuses on impairment provisions and estimated liabilities, which are accounting adjustments but presented as an official company announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about accounting provisions that does not fit other specific categories like Annual Report or Audit Report.
2026-04-20 Chinese
董事会审计委员会对会计师事务所2025年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm Tianjian Certified Public Accountants for the fiscal year 2025. It details the audit firm's qualifications, the process of their appointment, and the committee's oversight activities during the audit process. The document does not contain the full annual report or financial statements but focuses on the audit supervision and evaluation of the auditor's performance. This matches the definition of an Audit Report / Information filing, which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding the full Annual Report. The document length is 2298 characters, which is consistent with a detailed report but not a full annual report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2025
2026-04-20 Chinese
会计师事务所2025年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Tianjian for the year 2025. It discusses the firm's qualifications, independence, audit scope, and the audit results for the company's 2025 financial statements. The document includes detailed information about the audit firm's background, litigation history, and the audit process, concluding with an overall positive evaluation of the audit work. It is not the audit report itself but an assessment of the auditor's performance and compliance with regulations. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report focusing on the auditor's performance and audit results, not the full annual report or financial statements. The document length is 2628 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2025
2026-04-20 Chinese
关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of an upcoming earnings performance explanation meeting (业绩说明会) for the 2025 annual results and 2026 first quarter results. It provides the meeting time, location, participation method, and contact information. It does not contain actual financial statements or detailed financial analysis but rather invites investors to attend a live webcast where such information will be discussed. The document length is short (1494 characters) and it serves as a notice for an investor event rather than the event transcript or the financial report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or related to an earnings call event. However, since it is an announcement of the meeting rather than the transcript or presentation itself, and given the options, the closest classification is Investor Presentation (IP) because it is about a detailed presentation for investors focusing on financials and strategy, even though the actual presentation will occur later. Confidence is high due to clear keywords like "业绩说明会" (earnings explanation meeting), meeting details, and references to annual and quarterly results.
2026-04-20 Chinese
关于2025年限制性股票激励计划第一个归属期不符合归属条件暨作废已授予尚未归属的限制性股票的公告
Remuneration Information Classification · 95% confidence The document is an official announcement from Shanghai Heyuan Biotechnology (Group) Co., Ltd. regarding the cancellation and invalidation of unvested restricted stocks under the 2025 restricted stock incentive plan due to failure to meet vesting conditions and employee departures. It details the stock incentive plan, vesting conditions, performance targets, and the board's approval of the cancellation. The document is a formal disclosure of a corporate governance and compensation-related event, specifically about stock incentive plan adjustments and cancellations. It does not contain financial statements or quarterly/annual financial results, nor is it a report or presentation. It is not a proxy solicitation or voting result announcement. The content fits best under Remuneration Information (DEF 14A) as it relates to executive and employee compensation plans and their adjustments.
2026-04-20 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board regarding the independence of independent directors, referencing regulatory rules and self-assessment results. It does not contain financial data, audit results, or detailed management reports. It is a governance-related disclosure about board members' independence and compliance with listing rules. The document length is short (663 characters) and it is a formal opinion from the board on governance matters, not a full report or announcement of voting results. Therefore, it fits best under Governance Information (CGR).
2026-04-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.